Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

Immunity Pharma Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom Israel New York United States of America

Results from phase 2a trial in ALS patients were published in Muscle and Nerve.Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records.NfL was reduced by 27% for patients treated for at least two months.Unadjusted median survival for participants in the IPL344 group was 43.4 months compared with 19.1 months in the historical control group.IPL344 was safe and well-tolerated.View original content:https://www.prnewswire.co.uk/news-releases/immunity-pharma-presents-new-data-supporting-the-efficacy-of-ipl344-in-als-302421483.html